Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) PT at $38.80

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) has earned a consensus recommendation of "Buy" from the five ratings firms that are currently covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $38.80.

Several research analysts have issued reports on the company. Citigroup initiated coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price on the stock. Wedbush restated an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, April 16th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, insider Ross Moat sold 27,594 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total value of $800,777.88. Following the completion of the transaction, the insider owned 9,415 shares of the company's stock, valued at $273,223.30. This represents a 74.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Michael R. Megna sold 15,211 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $28.75, for a total value of $437,316.25. Following the completion of the transaction, the chief accounting officer directly owned 32,546 shares in the company, valued at approximately $935,697.50. This represents a 31.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 440,863 shares of company stock valued at $12,101,029. Company insiders own 53.48% of the company's stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nuveen LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter worth $16,992,000. Acadian Asset Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 170.3% in the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after purchasing an additional 651,700 shares during the last quarter. Braidwell LP increased its holdings in shares of Kiniksa Pharmaceuticals International by 19.3% in the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after purchasing an additional 557,934 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 149.1% in the first quarter. AQR Capital Management LLC now owns 491,761 shares of the company's stock worth $10,922,000 after buying an additional 294,319 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Kiniksa Pharmaceuticals International by 138.9% during the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock valued at $9,451,000 after buying an additional 277,827 shares during the last quarter. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Stock Up 0.7%

Shares of Kiniksa Pharmaceuticals International stock traded up $0.20 on Wednesday, reaching $27.44. The company's stock had a trading volume of 945,958 shares, compared to its average volume of 704,668. Kiniksa Pharmaceuticals International has a 52 week low of $17.82 and a 52 week high of $30.69. The firm's fifty day simple moving average is $27.09 and its two-hundred day simple moving average is $22.74. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -109.76 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The firm had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. During the same period in the prior year, the firm earned ($0.25) EPS. The company's revenue was up 72.5% compared to the same quarter last year. As a group, research analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.